IRRA - PT. Itama Ranoraya Tbk

Rp 2.480

-10 (-0,40%)

JAKARTA - Sales of PT Itama Ranoraya Tbk (IRRA) rose from Rp 265.62 billion in 2018 to Rp 281.75 billion in 2019. This increase also encouraged comprehensive profit growth to Rp 33.20 billion from Rp 32.26 billion.

As quoted from the Financial Report as of December 31, 2019 on Tuesday (3/3), the increase in sales was due to sales support for related parties. While sales to third parties fell from Rp 198, 16 billion or 74% of total sales in 2018, to Rp 126 billion or 44.72% of total sales in 2019.

The biggest contributor to sales came from the Directorate of Public Drug Management and Health Supplies as much as 18.98% of total sales to third parties amounting to Rp 126 billion, followed by UTD PMI DKI Jakarta Province Rp 36.81 billion, and PT Dharma Mitra Abadi amounting to Rp 35 71 billion.

Based on product segments, the biggest sales came from sterile non-electromedical medical devices products at Rp 118.39 billion, in vitro diagnostic products at Rp 144.97 billion, and other Rp 18.38 billion. (LK)